10-Q: Heartflow Reports Strong Revenue Growth Amidst IPO Transition

Heartflow, Inc. reported a 40% revenue increase in Q2 2025, driven by higher case volumes, as it transitioned to a public company following its August 2025 IPO.

Summary

• Revenue increased by 40% to $43.4 million for the three months ended June 30, 2025, compared to $31.1 million in the prior year period.
• Revenue for the six months ended June 30, 2025, grew 39% to $80.6 million, up from $57.9 million in the same period of 2024.
• Net loss significantly decreased by 61% to $9.2 million for Q2 2025, compared to $23.4 million for Q2 2024.
• Net loss for the six months ended June 30, 2025, was $41.5 million, a 6% improvement from $44.3 million in the prior year period.
• Heartflow revenue cases increased by 47% to 48,423 in Q2 2025, from 33,039 in Q2 2024.
• The company completed its Initial Public Offering (IPO) on August 11, 2025, raising approximately $332.8 million net of underwriting discounts and offering costs.
• Outstanding 2025 Convertible Notes, totaling $98.3 million, automatically converted into 6,470,743 shares of common stock at $15.20 per share upon IPO completion.
• The 2024 Term Loan, with an outstanding principal of $115.1 million as of June 30, 2025, was fully repaid in August 2025 using IPO proceeds.
• Accumulated deficit reached $1.0 billion as of June 30, 2025.
• Gross margin for Q2 2025 decreased to 75% from 77% in Q2 2024, primarily due to investments in hiring and training production team personnel.

Sentiment

Score: 6

Explanation: The company shows strong revenue and case volume growth, and a significant reduction in net loss, indicating positive operational momentum. The successful IPO and debt repayment strengthen its financial position. However, continued losses, a slight dip in gross margin, and high dependence on a single product, coupled with inherent industry risks, temper the overall positive sentiment, suggesting a 'hold' or 'neutral' stance for a seasoned investor.

Positives

• Strong revenue growth of 40% in Q2 2025 and 39% for the six months ended June 30, 2025, indicating increasing market adoption.
• Significant increase in Heartflow revenue cases by 47% in Q2 2025, demonstrating higher utilization of the platform.
• Net loss substantially reduced by 61% in Q2 2025 and 6% for the six-month period, showing progress towards profitability.
• Successful completion of an IPO in August 2025, raising significant capital of $332.8 million net, strengthening the company's financial position.
• Full repayment of the 2024 Term Loan in August 2025, reducing debt burden and associated interest expenses.
• Conversion of 2025 Convertible Notes into common stock upon IPO, simplifying the capital structure.
• Continued investment in research and development (R&D) to advance the Heartflow Platform and introduce new products like Heartflow PCI Planner (expected 2026).

Negatives

• Continued operating losses and an accumulated deficit of $1.0 billion as of June 30, 2025, indicating the company is not yet profitable.
• Gross margin decreased to 75% in Q2 2025 from 77% in Q2 2024, attributed to increased investment in production team hiring and training.
• Increased operating expenses, with R&D up 51% and Selling, General & Administrative up 12% in Q2 2025, reflecting growth investments but also higher costs.
• Dependence on Heartflow FFR CT Analysis, which represented 98% of total revenue as of June 30, 2025, posing concentration risk.
• Average sales price reduction due to a higher percentage of revenue cases from clinic and office-based accounts and increased utilization/volume rebates.
• Exposure to risks associated with AI model development, including potential for bugs, defects, errors, and evolving regulatory frameworks.

Risks

• Incurrence of significant net losses since inception and expectation of additional substantial losses in the foreseeable future, with no guarantee of achieving or sustaining profitability.
• High dependence on the success of Heartflow FFR CT Analysis, which currently generates almost all revenue, making the business vulnerable to factors negatively impacting this product.
• Potential unwillingness of healthcare providers to change standard practices for CAD evaluation, hindering adoption of the Heartflow Platform.
• Risk of inadequate or reduced reimbursement from third-party payors (government and commercial) for the Heartflow Platform, or changes in coding policies, negatively impacting adoption.
• Concentrated customer base, where the loss of a single large customer could result in a disproportionate loss across accounts.
• Significant competition in a rapidly changing medical technology environment, with competitors potentially developing more effective, accurate, reliable, or cost-effective products.
• Nascent commercialization of Heartflow Plaque Analysis, with no guarantee of achieving sufficient market acceptance or expected utilization levels.
• Operational challenges, legal liability, reputational concerns, and competitive risks associated with the use and development of AI models.
• Potential for disruption from catastrophic events (e.g., earthquakes, fires, pandemics, cyberattacks) affecting operations, IT systems, or supply chains.
• Failure to comply with extensive regulatory requirements (FDA, foreign authorities) for product marketing, potentially leading to sanctions, recalls, or delays.
• Exposure to product liability claims, which could result in costly litigation and significant liabilities, potentially exceeding insurance coverage.
• Risks related to the protection and enforcement of intellectual property rights, including patents, trade secrets, and trademarks, against infringement or challenges by third parties.
• Potential limitations on the ability to use net operating losses (NOLs) and tax credits to offset future taxable income due to ownership changes or insufficient taxable income.

Future Outlook

Management believes that the expected cash generated from revenue transactions with customers, existing cash and cash equivalents, and net proceeds from the August 2025 IPO will be sufficient to fund planned operating expenses and capital expenditure requirements for at least the next 12 months. The company expects to continue incurring losses in the foreseeable future as it scales its business, invests in R&D, and expands sales and marketing efforts. Heartflow PCI Planner is expected to launch in 2026.

Management Comments

• We believe that the expected cash generated from revenue transactions with customers and our existing cash and cash equivalents, together with the net proceeds from the IPO, will be sufficient to fund our planned operating expenses and capital expenditure requirements for at least the next 12 months from the date these condensed consolidated financial statements were available to be issued.
• We expect to continue to incur losses for the foreseeable future.
• We expect cost of revenue to increase as we hire additional personnel in our production team to support our increasing patient case volume.
• We expect our gross margin will increase over the long term as we leverage the AI-based nature of our software platform to automate an increasing number of the manual components of our production teams process, thereby lowering the cost of revenue per analysis.
• We expect increased revenues from our Heartflow Plaque Analysis to positively impact our gross margin, as it runs on the same CCTA scan as Heartflow FFR CT Analysis.
• We expect our research and development expenses to increase as we conduct clinical studies for expanded indications for use and to hire additional personnel to develop new product offerings and product enhancements.
• We expect that our selling, general and administrative expenses will increase in the future as a result of expanding our operations, including hiring personnel, to both drive and support anticipated growth as well as various incremental costs associated with operating as a public company.

Industry Context

Heartflow operates in the medical technology industry, specializing in non-invasive coronary artery disease (CAD) detection using software and AI. The company's growth is tied to the adoption of CCTA and AI-powered diagnostics, a trend that is gaining traction in healthcare. The industry is highly competitive, with both traditional diagnostic providers and emerging AI-based platforms. The company's focus on enhancing workflow efficiency and providing actionable insights aligns with broader industry demands for improved diagnostic accuracy and cost-effectiveness. Regulatory changes, such as those from the FDA and CMS, significantly influence market dynamics and reimbursement, impacting the commercial success of new technologies.

Comparison to Industry Standards

• Heartflow's 47% increase in revenue cases (Q2 2025) suggests strong adoption relative to the general growth rate of traditional non-invasive CAD tests like SPECT, stress echocardiography, and PET, which are established but may offer less differentiated accuracy.
• The company's reliance on Heartflow FFR CT Analysis for 98% of its revenue highlights a concentration risk compared to diversified medical technology companies like GE Healthcare, Siemens Healthineers AG, and Koninklijke Philips N.V., which offer a broad range of diagnostic equipment and services.
• The decrease in gross margin to 75% in Q2 2025, while still robust, indicates significant investment in scaling operations, which is common for high-growth medical technology companies expanding their commercial footprint and R&D.
• Heartflow's AI-powered platform competes with earlier-stage companies like Cleerly, Inc., Elucid Bioimaging Inc., and Keya Medical Technology Co., Ltd., which are also developing AI-based CCTA analysis tools. Heartflow's established regulatory clearances (FDA for FFR CT in 2014, Plaque Analysis in 2022) and broader installed base (almost 500,000 patients assessed) provide a competitive advantage over these newer entrants.
• The company's strategy to launch Heartflow PCI Planner in 2026 positions it to compete in the revascularization planning segment, potentially expanding its market beyond pure diagnostics, similar to how larger players integrate various stages of cardiac care.

Management Changes

Corporate Governance

Legal Proceedings

• Not involved in any pending legal proceedings that are believed to have a material adverse effect on financial condition, results of operations, or cash flows.
• May pursue or be subject to litigation and other legal actions from time to time arising in the ordinary course of business, including intellectual property, product liability, breach of contract, commercial, employment, and other similar claims.

Related Party Transactions

• The 2025 Convertible Notes, totaling $98.3 million, were issued to 'various investors and certain employees (the Requisite Holders), including related parties'.

Stakeholder Impact

• **Shareholders:** Potential for dilution from future equity issuances, stock price volatility, and the impact of ongoing losses. However, the IPO and debt repayment improve financial stability and growth prospects.
• **Employees:** Benefit from new equity incentive plans (2025 Performance Incentive Plan, 2025 Employee Stock Purchase Plan) and recent option/RSU grants, aligning their interests with company performance. Continued hiring in production and R&D teams indicates job growth.
• **Customers (Healthcare Providers):** Continued adoption of Heartflow Platform, especially FFR CT Analysis, indicates value. However, potential changes in reimbursement policies and average sales price reductions could impact their economic incentives.
• **Creditors:** The full repayment of the 2024 Term Loan significantly reduces the company's debt obligations, improving its credit profile.
• **Suppliers:** Reliance on third-party CCTAs and contrast agents means any disruption to these suppliers could impact Heartflow's operations.

Next Steps

• Continue to scale the business and invest in research and development activities.
• Increase sales and marketing efforts to support commercial expansion.
• Increase general and administrative expenses to support operating as a public company.
• Launch Heartflow PCI Planner in 2026.
• Conduct clinical studies for expanded indications for use and develop new product offerings and enhancements.
• Evaluate the impact of ASU 2023-09 (Income Tax Disclosures) for the year ended December 31, 2025.
• Evaluate the impact of ASU 2024-03 (Income Statement Expense Disaggregation) for fiscal years beginning after December 15, 2026.
• Evaluate the impact of ASU 2025-05 (Credit Losses for Accounts Receivable) for fiscal years beginning after December 15, 2025.

Key Dates

Recommendation

Heartflow, Inc. demonstrates strong operational growth with significant increases in revenue and case volumes, indicating growing market acceptance for its core product. The successful IPO and subsequent full repayment of its term loan have substantially improved its liquidity and balance sheet, reducing financial risk. However, the company continues to incur net losses and has a substantial accumulated deficit, highlighting that profitability is still a future objective. The business remains highly dependent on its FFR CT Analysis, and while new products are in development, their commercial success is unproven. The competitive landscape, evolving regulatory environment, and inherent risks associated with AI technology and healthcare reimbursement present ongoing challenges. For a seasoned investor, the current situation presents a mixed bag of strong growth potential and significant execution risks. A 'hold' recommendation is appropriate, suggesting investors maintain their current position while closely monitoring the company's progress towards sustained profitability, successful new product launches, and effective navigation of competitive and regulatory pressures.

Keywords

Coronary Artery Disease, Medical Technology, Artificial Intelligence, FFR CT Analysis, Plaque Analysis, Cardiology, Healthcare Diagnostics, SEC Filing, 10-Q, IPO, Financial Results, Stock Options, Convertible Notes, Term Loan